“The rap on St. Louis’ biotech industry is that all of its startups are years away from selling products, with no big success stories yet. Don’t tell that to Ed Weinstein, co-founder and chief executive of Canopy Biosciences. Canopy is launching its first product just months after being founded, and it expects to quickly achieve […]
iGTRCN reviews a recent paper by Sergej Djuranovic’s lab at Washington University in St. Louis detailing the technology at the heart of our TUNR system. Read the entire iGTRCN article
Canopy featured in the St. Louis Business Journal! Read all about us here. “Canopy Biosciences, a young startup looking to accelerate the commercialization of life science reagent tools and services, has raised $2 million from investors.” Canopy looks to in-license — essentially a collaboration agreement between two parties in which one company performs the R&D […]
Full speed. Half speed. Full stop. Those are the usual choices for controlling the amount of protein produced from a particular gene. Other speeds are possible, but they typically require a lot of effort on the part of scientists, who often resort to the identification and exploitation of a hypomorphic mutation, that is, a mutation […]